The SERENA-2 trial (phase II, camizestrant in ER+/HER2− advanced breast cancer) demonstrated that camizestrant significantly prolonged progression-free survival (PFS) compared with fulvestrant in ESR1-mutant patients [54]. Here, ESR1 is linked to breast cancer.